Brokerages Set Gyre Therapeutics, Inc. (NASDAQ:GYRE) PT at $17.00

Gyre Therapeutics, Inc. (NASDAQ:GYRE) has received an average recommendation of “Hold” from the five brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $17.00.

GYRE has been the subject of several research reports. Wall Street Zen raised Gyre Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Jefferies Financial Group started coverage on Gyre Therapeutics in a research note on Friday, October 10th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th.

Gyre Therapeutics Price Performance

Shares of NASDAQ GYRE opened at $8.09 on Thursday. The company has a market cap of $779.31 million, a PE ratio of 269.76 and a beta of 1.99. Gyre Therapeutics has a 1-year low of $6.11 and a 1-year high of $13.75. The stock has a fifty day moving average price of $7.64 and a 200 day moving average price of $7.66.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC bought a new position in shares of Gyre Therapeutics in the third quarter valued at approximately $267,000. Alliancebernstein L.P. grew its stake in Gyre Therapeutics by 9.5% in the 3rd quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock valued at $163,000 after buying an additional 1,900 shares during the last quarter. Lazard Asset Management LLC bought a new position in Gyre Therapeutics in the 3rd quarter worth $111,000. Strs Ohio raised its holdings in Gyre Therapeutics by 58.6% in the 3rd quarter. Strs Ohio now owns 21,100 shares of the company’s stock worth $157,000 after acquiring an additional 7,800 shares during the period. Finally, State of Alaska Department of Revenue acquired a new position in Gyre Therapeutics during the 3rd quarter worth $38,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.